|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
We wanted you to be aware that the FDA has granted accelerated approval of IBRANCE® (palbociclib) for the treatment of postmenopausal women with ER+/HER2- advanced breast cancer. Click here to see the press release!
We wanted you to be aware that FDA-approved Hysingla™ ER (hydrocodone bitartrate) extended-release tablets CII has commercially launched in the U.S.
Please click here to view the press release.
Click here for a CME/CEU activity on Improving Treatment of Atrial Fibrillation and Stoke
Otezla® (apremilast) is approved for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Please click here for more information.
Click here to view our Complimentary Online CME/CEU Webcasts
23andMe finds genes for motion sickness
The personal genomics company 23andMe has identified 35 genetic factors tied to motion sickness, according to a new study published in the journal Human Molecular Genetics.
In what the company says is the first ever genome-wide study looking at motion sickness, 23andMe was able to determine several genes that may be tied to the nausea associated with movement in a car or on a boat.
Light-activated genes might be precisely controlled and targeted
Duke University researchers have devised a method to activate genes in any specific location or pattern in a lab dish with the flip of a light switch by crossing a bacterium's viral defense system with a flower's response to sunlight.
Gene changes make humans' sense of taste unique
Our relationship with food is part of being human. Meals are time for ritual and a chance to strengthen social bonds over the work of cooking and eating. But what and how we eat also helped make us human, to begin with: Changes in our eating habits also shaped our genes.
Personalized medicine is promising but needs smarter regulation
In a high-profile White House event attended by medical researchers, patients’ advocates and drug and biotechnology company executives on Jan. 30, President Barack Obama plugged medicine’s new mantra, “the right dose of the right drug for the right patient at the right time.”
BioFeedback for immunoglobulin is a health outcomes reporting program that provides clinical feedback on the use of immunoglobulin in autoimmune-related disorders. Physicians and medical directors can now deploy clinical interventions when they have the greatest impact on healthcare quality and costs.
Request more information or schedule a personal introduction.
The problem with precision medicine
The New Yorker
Recently, in a speech at the White House, President Barack Obama unveiled what he called his Precision Medicine Initiative, a $215 million plan to collect genetic information from a million American volunteers in order to further the development of personalized, genetics-based medical treatments. Obama called precision medicine “one of the greatest opportunities for new medical breakthroughs that we have ever seen,” saying that it promised to deliver “the right treatments at the right time, every time, to the right person.”
Medicine just for you
The New York Times
President Barack Obama’s new budget contains a farsighted proposal that could ultimately transform the practice of American medicine. The proposal seeks to design treatments for the individual, which are sometimes called “personalized medicine” or “precision medicine” to distinguish them from the one-size-tries-to-fit-all approach.
Stem cells can repair brain damage from radiation therapy
Radiation Therapy News
Researchers at the Memorial Sloan Kettering Cancer Center recently reported that it was possible to repair brain damage caused by radiation therapy for brain cancer by using lab-generated cells derived from human stem cells. The study was published in the journal Cell Stem Cell, and entitled “Human embryonic stem cell-derived oligodendrocyte progenitors remyelinate the brain and rescue behavioral deficits following radiation.”
Creative Medical seeks patent for stem cell therapy for MS
Multiple Sclerosis News Today
Phoenix-based Creative Medical Health has just announced it has submitted a patent application for its proprietary mesenchymal stem cell pipeline product, indicated for autoimmune diseases. The company is already preparing to launch the product into its first line of clinical tests, which will focus first on multiple sclerosis.
EMERGING MEDICAL TECHNOLOGIES
Vendors lagging with patient engagement technology
Healthcare IT News
Despite conditions across the healthcare industry that should be driving big changes in between-visit and post-discharge communications, most providers are still doing the "bare minimum" with regard to patient engagement, according to a new report from Chilmark Research.
Advances in mobile and cloud technologies, consumerization of care delivery, meaningful use incentive payments and a broader move toward value-based reimbursement would seem to be creating ripe conditions for more fruitful engagement initiatives.
How integrating technologies can change the way healthcare is delivered
What do Google’s driverless car, a cab service company and an online medical care scheduling service have in common? Nothing really, but in the perfect world, they’d be working together to deliver the perfect healthcare solution in our society.
Skeptical? Technology has already started to transformed the healthcare industry.
ACCOUNTABLE CARE ORGANIZATIONS
Groups weigh in on health IT provisions of CMS' ACO program
Healthcare organizations are urging CMS to provide more real-time data to accountable care organizations participating in the Medicare Shared Savings Program, Health Data Management reports. The letters came in response to a proposed rule released by CMS in December 2014 that includes provisions designed to increase health IT use among MSSP participants.
Accountable care takes new forms as fee-for-service fades
Health IT Analytics
Accountable care agreements are proliferating in shape and structure as healthcare providers begin to leave behind fee-for-service reimbursement in earnest. While hundreds of new organizations are engaging in the standard risk-sharing arrangement every year, some are taking collaborative care and population health management to new heights with innovative structures to improve care quality and reduce costs.
FDA: NEW TREATMENTS AND TECHNOLOGY
FDA clears 1st neck-access neuroprotection for carotid stenting
The U.S. Food and Drug Administration has cleared the Enroute Transcarotid Neuroprotection System to reduce the risk for stroke during carotid angioplasty and stenting, the first such device to use neck rather than groin access.
Anticoagulant Savaysa now available for prescribing
Daiichi Sankyo announced that Savaysa tablets are now available to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment of deep vein thrombosis and pulmonary embolism following 5–10 days of initial therapy with a parenteral anticoagulant.
CMS plans to shorten meaningful use Stage 2 to 90 days
By Scott Rupp
The Centers for Medicare & Medicaid Services buckled, or so it seems. After much conjecture, gesturing and soapbox shouting from healthcare leaders, it looks like the reporting period for sending data collected in the electronic health record as part of meaningful use Stage 2 will be shortened from 365 days to 90. According to SearchHealthIT, "The time and money required to attest for a 365-day reporting period gave heartburn to many hospitals and physicians."
You have a week left to get health insurance this year
The Obamacare deadline to sign up for a policy is Feb. 15. Here's what you need to do to make sure you're covered. Time is running out. The open enrollment period for buying individual health insurance for 2015 ends Feb. 15. Miss this important deadline, and you could remain uninsured all year — and face a steep tax penalty.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063